Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine Glucuronide SCHEMBL612431 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL6754812 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL17302928 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL152647 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL12082244 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13267437 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13268600 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13245908 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL5674614 | 0.99 | OPRM1 (0.98) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL5674692 | 0.97 | OPRM1 (0.94) | OPRM1MRGPRX2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267985-A1 | MUTANT LACTOBACILLUS BETA-GLUCURONIDASE ENZYMES WITH ENHANCED ENZYMATIC ACTIVITY | INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC. | 2017-09-21 | — | — | US | claimed |
| US-20160237415-A1 | MUTANT STAPHYLOCOCCUS BETA-GLUCURONIDASE ENZYMES WITH ENHANCED ENZYMATIC ACTIVITY | INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC. | 2016-08-18 | — | — | US | claimed |
| US-8481559-B2 | Morphine and morphine precursors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2013-07-09 | — | — | US | claimed |
| US-20110130356-A1 | MORPHINE AND MORPHINE PRECURSORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2011-06-02 | — | — | US | claimed |
| US-20080221143-A1 | Inducing nitric oxide release from cells; to treat diseases, to reduce inflammation, or to restore normal function | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NY (US) | 2008-09-11 | — | — | US | claimed |
| EP-1809283-A2 | MORPHINE AND MORPHINE PRECURSORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-07-25 | — | — | EP | claimed |
| US-20060088607-A1 | Nutritional supplement compositions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-27 | — | — | US | claimed |
| WO-2006039691-A2 | MORPHINE AND MORPHINE PRECURSORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-04-13 | — | — | WO | claimed |
| US-12617790-B2 | Mitragynine analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4212532-A2 | MITRAGYNINE ANALOGS AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220024923-A1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024978-A1 | PEPTIDES COMPRISING OPIOID RECEPTOR AGONIST AND NK1 RECEPTOR ANTAGONIST ACTIVITIES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-01-27 | — | — | US | disclosed |
| US-11141452-B2 | Bifunctional compounds for relief of pain comprising an opioid receptor agonist moiety and a NK1 receptor antagonist moiety and methods for treating pain | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-10-12 | — | — | US | disclosed |
| WO-2000004046-A2 | MULTIPLE SPLICE VARIANTS OF THE MU-OPIOID RECEPTOR GENE | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-2000003716-A1 | TOPICAL COMPOSITIONS COMPRISING AN OPIOID ANALGESIC AND AN NMDA ANTAGONIST | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-2000003716-A1 | TOPICAL COMPOSITIONS COMPRISING AN OPIOID ANALGESIC AND AN NMDA ANTAGONIST | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5908927-A | Synthesis of deuterated opiate glucuronides | HIGH STANDARD PRODUCTS CORPORATION (US) | 1999-06-01 | — | — | US | disclosed |
| US-5908927-A | Synthesis of deuterated opiate glucuronides | HIGH STANDARD PRODUCTS CORPORATION (US) | 1999-06-01 | — | — | US | disclosed |
| EP-0632041-A1 | New morphine derivatives having improved analgesic and narcotic properties | KATHOLIEKE UNIVERSITEIT NIJMEGEN (NL) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617790-B2 | Mitragynine analogs and uses thereof | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885MRGPRX2 128/4885OPRD1 4/4885 |
| US-11141452-B2 | Bifunctional compounds for relief of pain comprising an opioid receptor agonist moiety and a NK1 receptor antagonist moiety and methods for treating pain | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885MRGPRX2 15/4885OPRD1 4/4885 |
| US-20220024923-A1 | MITRAGYNINE ANALOGS AND USES THEREOF | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885MRGPRX2 23/4885OPRD1 4/4885 |
| US-20220024978-A1 | PEPTIDES COMPRISING OPIOID RECEPTOR AGONIST AND NK1 RECEPTOR ANTAGONIST ACTIVITIES | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885MRGPRX2 11/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.